World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 1

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5748)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

134

HTML

3303

Figures (1-2)

448

Tables (1-5)

471

Sum=4356

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

212

Download

913

Sum=1125

Jan 7, 2025 (publication date) through Mar 16, 2026

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Gao W, Li JW, Ye H, Zhang XZ, Liu JX, Cheng H. Real-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori treatment in elderly patients. World J Gastroenterol 2025; 31(1): 101463 [PMID: 39777248 DOI: 10.3748/wjg.v31.i1.101463]
URL:	https://www.wjgnet.com/1007-9327/full/v31/i1/101463.htm

Number	Citing Articles
1	Xue Fan, Yanyan Shi, Yuan Li, Xiangchun Lin. Comparison of Vonoprazan and Low-Dose Amoxicillin Dual Therapy with Bismuth-Containing Quadruple Therapy for Naïve Helicobacter pylori Eradication: A Single-Center, Open-Label, Randomized Control Trial. Antibiotics 2025; 14(10): 990 doi: 10.3390/antibiotics14100990
2	Ruyi Qi, Feng Zhou. Efficacy analysis of a bismuth-containing quadruple therapy with vonoprazan for Helicobacter pylori infection . Scandinavian Journal of Gastroenterology 2026; : 1 doi: 10.1080/00365521.2026.2622659
3	Subeikshanan Venkatesan, Brandon Lucke-Wold. Mind the gut: Navigating the complex landscape of gastroprotection in neurosurgical patients. World Journal of Gastroenterology 2025; 31(8): 102959 doi: 10.3748/wjg.v31.i8.102959 Abstract(570) \| Core Tip(515) \| Full Article(HTML)(2492) \| Full Article with Cover (PDF)-676K(148) \| Audio-1162K(26) \| Peer-Review Report-275K(92) \| Answering Reviewers-13K(82) \| Full Article (PDF)-409K(184) \| Full Article (XML)-114K(91) \| Times Cited (7) \| Total Visits (5625) \| Open
4	Mubin Ozercan, Ahmed Tawheed, Alaa Ismail, Mohab Sherif Amer, Mohamed El-Kassas. Vonoprazan and proton pump inhibitors: Which is superior for <i>Helicobacter pylori</i> eradication?. World Journal of Gastroenterology 2025; 31(17): 103156 doi: 10.3748/wjg.v31.i17.103156 Abstract(366) \| Core Tip(461) \| Full Article(HTML)(6116) \| Full Article with Cover (PDF)-1873K(150) \| Audio-156K(14) \| Peer-Review Report-217K(86) \| Answering Reviewers-59K(83) \| Full Article (PDF)-410K(265) \| Full Article (XML)-111K(77) \| Times Cited (1) \| Total Visits (8935) \| Open
5	Jin‐Yan Zhang, Ji Li, Wei‐Feng Huang, Xiao‐Yi Lei, Yu‐Lin Huang, Gui‐Hua Xu, Dong Xu. Efficacy and Safety of Vonoprazan‐Based Dual, Triple, and Quadruple Therapies for Helicobacter pylori Eradication: A Randomized Controlled Trial. Helicobacter 2026; 31(2) doi: 10.1111/hel.70112
6	Sowmya Errabaka, Haritha Pasupulati, Satyanarayana SV Padi. PRAZANs or PCABs, Potassium Competitive Acid Blockers: A New Therapeutic Class in Acid-Related Diseases. International Journal of Health Sciences and Research 2026; : 109 doi: 10.52403/ijhsr.20260215